Back to results
US 8,236,294 B2Granted
Gene therapy using transposon-based vectors
AssigneesBoard of Supervisors of Louisiana State University and Agricultural and Mechanical College, TransGenRx, Inc.
InventorsRichard K. Cooper, Frederick M. Enright, William C. Fioretti
Life of this patent
Estimating the term…
Abstract
Methods and compositions are presented for the administration of transposon-based vectors to an animal or human to provide gene therapy to the animal or human.
Claims23
A method of providing gene therapy to an animal or a human to treat a disease or a condition comprising:
- administering to the animal or the human a transposon-based vector in an acceptable carrier, the transposon-based vector comprising an isolated polynucleotide sequence encoding:
- a) a gene operably linked to a first promoter, the gene encoding for a transposase;
- and,
- b) one or more genes of interest operably-linked to one or more additional promoters, wherein the one or more genes of interest and their operably-linked promoters are flanked by transposase insertion sequences recognized by the transposase, and wherein the first promoter and the one or more additional promoters are cell-specific promoters or constitutive promoters, wherein the one or more genes of interest codes for production of a peptide comprising a lytic peptide,
- wherein the disease or condition is cancer and the cancer cells have a receptor for GnRH or LH, and
- wherein the transposon-based vector in the acceptable carrier is administered directly to the cancer cells.
3 more elements
A method of providing gene therapy to an animal or a human to treat a cancer comprising:
- administering to the animal or the human having the cancer a transposon-based vector in an acceptable carrier, the transposon-based vector comprising an isolated polynucleotide sequence encoding:
- a) a gene operably linked to a first promoter, the gene encoding for a transposase;
- and,
- b) one or more genes of interest operably-linked to one or more additional promoters, wherein the one or more genes of interest and their operably-linked promoters are flanked by transposase insertion sequences recognized by the transposase, and wherein the first promoter and the one or more additional promoters are cell-specific promoters or constitutive promoters, wherein the one or more genes of interest codes for production of a peptide comprising a fusion peptide comprising a lytic peptide and a peptide recognized by a cell surface receptor on the cancer cell.
1 more element
Dependencies are inferred from the claim text.